CEA Testing is NOT Recommended for Routine Breast Cancer Surveillance
CEA testing should not be used for routine surveillance in patients who have completed curative-intent therapy for breast cancer. 1
Clear Guideline Recommendation
The American Society of Clinical Oncology (ASCO) explicitly states that CEA is not recommended for screening, diagnosis, staging, or routine surveillance of breast cancer patients after primary therapy 2. This recommendation has remained unchanged since 2000 and was reaffirmed in the 2013 guideline update after reviewing literature through 2012 1.
What Should Be Done Instead
For routine surveillance after curative-intent therapy:
- Physical examination: Every 3-6 months for years 1-3, every 6-12 months for years 4-5, then annually
- Mammography: Annually (with specific timing after breast-conserving surgery)
- History taking: At each visit, focusing on symptoms of recurrence
No laboratory testing (including CEA, CA 15-3, CA 27.29, CBC, chemistry panels) is recommended for asymptomatic patients with normal physical examination 1.
Why CEA is Not Useful for Surveillance
The evidence demonstrates several critical limitations:
- Low sensitivity: Only 50-60% of patients with metastatic disease have elevated CEA levels 2
- Inferior to alternatives: CEA is less commonly elevated than CA 15-3 or CA 27.29 (which detect 75-90% of metastatic disease) 2
- Negative lead time: A Japanese study found CEA elevation occurred an average of 334 days AFTER clinical recurrence was already detected, not before 3
- No survival benefit: Studies show that intensive surveillance with tumor markers does not improve overall survival or disease-free survival 4
- Poor cost-effectiveness: CEA monitoring is expensive and inefficient compared to other markers 5
When CEA May Have Limited Utility
CEA testing has a restricted role only in the metastatic disease setting, not for surveillance:
- For monitoring patients already diagnosed with metastatic disease during active therapy
- Must be used in conjunction with imaging, history, and physical examination—never alone
- Only useful if CA 15-3/CA 27.29 is not elevated (CEA adds information in only about 6% of cases) 2
- An increasing CEA may indicate treatment failure in the absence of measurable disease
- Caution: Spurious early rises can occur in the first 4-6 weeks of new therapy 2
Common Pitfall to Avoid
Despite clear guidelines against routine CEA testing, it remains widely performed in some countries, particularly in Asia 3. This practice wastes resources and does not benefit patients. Recent 2023 data confirms that more intensive surveillance strategies (including tumor markers) provide no improvement in overall survival compared to standard follow-up 4.
The evidence is unequivocal: CEA has no role in routine breast cancer surveillance after curative-intent therapy. Save CEA testing exclusively for the limited scenario of monitoring known metastatic disease when CA 15-3/CA 27.29 is not informative.